Rituximab Associated Necrosis: A Case Report Publisher Pubmed



Ashtari F¹ ; Hakamifard A² ; Hariri A³ ; Gholipourshahraki T⁴
Source: Multiple Sclerosis and Related Disorders Published:2020

Abstract

Background: Rituximab is a B-cell-depleting unconjugated monoclonal IgG1 antibody that targets the transmembrane protein CD20. This article reports on a case with the rare complication known as Rituximab-associated mucosal necrosis. Case presentation: The present case report addresses, for the first time, a patient affected by Devic's syndrome presenting with oral manifestations of palatal necrosis after rituximab treatment. Conclusion: The present case raises the possibility of anti-CD20 antibody contributing to the development of palatal mucosal necrosis in some patients. Given the increasing administration of rituximab as a result of its efficacy against several diseases, a report on the potential iatrogenic effects of this drug is essential. © 2019 Elsevier B.V.